Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News PharmaTher Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (CSE:PHRM)

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Newsfile February 2, 2026

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Newsfile January 14, 2026

PharmaTher CEO Publishes Letter to Shareholders

Newsfile January 2, 2026

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Newsfile December 2, 2025

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Newsfile November 17, 2025

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Newsfile October 17, 2025

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

Newsfile October 16, 2025

PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

Newsfile October 15, 2025

CSE Bulletin: MOC Eligibility Update

Newsfile October 9, 2025

Opinion & Analysis (CSE:PHRM)

No current opinion is available.

Bullboard Posts (CSE:PHRM)

RE:RE:Thoughts

Gotcha, hopefully we start to see some milestone payments and partnerships. Investor confidence is definitely lost.
Tommyjohn - January 2, 2026

RE:Thoughts

Best case scenario, Caplin has good sales - the profit share split is favorable as well as milestones. They favorably license or sell...
Itistoo - December 26, 2025

Thoughts

 Anybody have any thoughts for the new year on our future here.
Tommyjohn - December 23, 2025

RE:RE:RE:Why

Keep staying bitter
StockReco - November 25, 2025

RE:RE:Why

stocretrograde: Another keyboard whak trying to one up himself with brutal mischaracter? Like a putz? You bet!!!! ...pg
polygraph46 - October 25, 2025

RE:RE:Why

Itistoo: Thank you for those observations..pg
polygraph46 - October 25, 2025

Podcasts